Neurocrine Biosciences To Present At UBS Global Healthcare Conference; Webcast At 4:15 PM ET

RTTNewsNov 12 15:03 ET

AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio

BenzingaNov 12 13:52 ET

AbbVie's Disappointing Schizophrenia Drug Trial Bodes Well for Rival Bristol Myers, Analysts Say

MarketWatchNov 12 08:53 ET

Oppenheimer Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $192

Moomoo NewsNov 12 08:31 ET · Ratings

Jefferies Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $158

Moomoo NewsNov 12 08:31 ET · Ratings

Neurocrine (NBIX) Gets a Buy From Oppenheimer

TipRanksNov 12 07:47 ET · Ratings